首页> 外文期刊>Antiviral Research >Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection.
【24h】

Characterization of a cidofovir-resistant HHV-6 mutant obtained by in vitro selection.

机译:通过体外选择获得的耐西多福韦的HHV-6突变体的表征。

获取原文
获取原文并翻译 | 示例
           

摘要

Cidofovir (CDV) was used for in vitro selection of a human herpesvirus 6 (HHV-6) mutant with decreased susceptibility to this drug. The resulting mutant was highly resistant to CDV as compared to its sensitive counterpart (inhibitory concentration 50% (IC50): 213 microM versus 1.8 microM). Its replication fitness was not impaired. Genotypic characterization of the resistant virus revealed a mutation in the U38 gene encoding the viral DNA polymerase. The resulting R798I amino acid change was located in the conserved domain VII close to the highly conserved motif KKRY interacting with the DNA primer-template duplex, and is likely responsible for the high-level resistance to CDV, even though a definite virological and/or biochemical confirmation is required. The possible emergence of such changes in HHV-6 DNA polymerase in patients receiving CDV therapy should be taken into account in the treatment of HHV-6 infections.
机译:西多福韦(CDV)用于体外选择对这种药物敏感的人疱疹病毒6(HHV-6)突变体。与其敏感的对应物相比,所得突变体对CDV具有高度抗性(抑制浓度50%(IC50):213 microM对1.8 microM)。它的复制适应性没有受到损害。抗性病毒的基因型特征表明,编码病毒DNA聚合酶的U38基因发生突变。产生的R798I氨基酸变化位于与DNA引物-模板双链体相互作用的高度保守基序KKRY的保守结构域VII中,即使有一定的病毒学和/或病毒学意义,也可能对CDV产生了高水平抗性必须进行生化确认。在治疗HHV-6感染时,应考虑接受CDV治疗的患者中HHV-6 DNA聚合酶这种变化的可能出现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号